Teams of researchers are investigating empagliflozin and dapagliflozin in patients with autosomal dominant polycystic kidney ...

NEW ORLEANS -- Patients at a community health center who had type 2 diabetes and a high risk of atherosclerotic ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

Diabetes and heart health are closely connected. People with diabetes have a higher risk of heart failure, a condition where ...

Researchers have discovered that sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor ...

November is Pet Diabetes Month. Signs to look out for are increased drinking, urination, appetite, weight loss, lethargy, and ...

A newer type of diabetes medication called sodium-glucose cotransporter-2 (SGLT2) inhibitors has been linked to a rare but ...

SGLT2 inhibitors are a new family of agents, which occlude the path of SGLT2 glucose reabsorption and cause glucosuria. Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and ...

Given that SGLT2 drugs have been shown to prevent heart failure in studies involving people with diabetes and kidney disease, and reduce progression in those who already have it, the study hoped ...

Newer glucose-lowering drugs reduce the risk for late-onset seizures and epilepsy by 24%, with GLP-1 RAs cutting the risk by ...